跳至主要内容
临床试验/NCT04455906
NCT04455906招募中不适用

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

Boston Children's Hospital2 个研究点 分布在 1 个国家目标入组 111 人开始时间: 2020年11月30日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
111
试验地点
2
主要终点
atopic dermatitis severity

研究概览

简要总结

This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.

详细描述

For this study, participants ages 6-65 years, who have atopic dermatitis and don't have any of the exclusion criteria will be invited to participate in the study. There will be a 1 time visit where questionnaires, blood draw, skin swab and skin biopsies will be performed.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
6 Years 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female participants ≥6 to 65 yrs of age
  • Meet AD Standard Diagnostic Criteria

排除标准

  • Enrollment in another clinical trial
  • Hypersensitivity to an agent used for the skin decolonization protocol
  • Use within 4 weeks of systemic treatment with immunosuppressive/immunomodulating drugs (corticosteroids, cyclosporine, mycophenolate, JAK inhibitors, azathioprine, methotrexate)
  • Phototherapy for AD within 4 weeks
  • Treatment with biologics (dupilumab, omalizumab, benralizumab, etc) within sixteen weeks
  • Use of topical steroids, topical calcineurin inhibitors or crisaborale within 7 days
  • Bleach baths within 7 days of the first Visit
  • Use of oral or topical antibiotics within 21 days of the beginning of the study
  • Asthmatics receiving more than 500 μg per day of inhaled corticosteroids
  • History of (HIV, hepatitis B, hepatitis C, tuberculosis malignancy
  • Skin comorbidities that may interfere with assessments: psoriasis, cutaneous T Cell lymphoma,,
  • Severe ongoing medical illnesses e.g. cardiovascular, renal disease, autoimmune disease.
  • Febrile illness at time of visits
  • Suspected immune deficiency or family history of primary immunodeficiency

结局指标

主要结局

atopic dermatitis severity

时间窗: baseline, only 1 time point

validated assessment EASI score

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Wanda Phipatanakul

Professor of Pediatrics, Director Asthma Research Center

Harvard Medical School (HMS and HSDM)

研究点 (2)

Loading locations...

相似试验